Clinical Characteristics of Peripheral Neuropathy in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Single-Center Study in China

Table 2

Comparison of baseline features between EGPA patients with PN and without PN.

Characteristics	With PN	Without PN	value
Demographics
Age (year, x ± S)	47±12.9	43±14.0	0.096
Gender (male/female, n)	27/24	33/26	0.753
Time from allergy to EGPA diagnosis (month), median (IQR)	24(3,84)	24(6,62)	0.942
Disease duration(month), median (IQR)	7(2,19)	4(2,15)	0.308
Time from initial symptoms to EGPA diagnosis (month), median (IQR)	12(0,48)	6 (0,42)	0.423
Clinical manifestation [n (%)]
Weight loss	25(49.0)	16(27.1)	0.018
Fever	24(47.1)	21(35.6)	0.223
Arthritis or joint pain	12(23.5)	5(8.5)	0.029
Myalgia	14(27.5)	8(13.6)	0.069
Allergic rhinitis	15(29.4)	25(42.4)	0.159
Asthma	40(78.4)	45(76.3)	0.787
Cutaneous vasculitis	26(51.0)	33(55.9)	0.604
Renal involvement	16(31.4)	12(20.3)	0.185
Digestive tract involvement	20(39.2)	16(27.1)	0.178
CNS involvement	11(21.6)	8(13.6)	0.268
Heart involvement	20(39.2)	20(33.9)	0.563
Ear involvement	8(15.7)	6(10.2)	0.387
Sinusitis	29(56.9)	35(59.3)	0.794
Eos count (×10^9/L), median (IQR)	3.3(1.3,9.1)	2.7(1.3,5.8)	0.827
Clinical score
BVAS [recent 4 weeks, median (IQR)]	18(14,22)	12(8,16)	<0.0001
FFS ≥1[n (%)]	31(60.8)	25(42.4)	0.054

PN: peripheral neuropathy; CNS: Central Nervous System; Eos: eosinophil; BVAS: Birmingham Vasculitis Activity Score; FFS: five factor score; .